Genscript Biotech’s Core Earnings Surge but Legend Impairment Drives 2025 Net Loss

Genscript Biotech ( (HK:1548) ) just unveiled an announcement.

Genscript Biotech reported a sharp acceleration in operating performance for 2025, with revenue from continuing operations surging 61.4% to US$959.5 million, driven largely by a substantial rise in license income and solid growth across other business lines. Gross profit more than doubled to US$553.2 million, while adjusted net profit from continuing operations jumped 285% to US$230.3 million, reflecting strong underlying business momentum.

Despite these operational gains, the group posted a net loss of US$532.4 million, in contrast to a US$2.9 billion profit a year earlier, mainly due to its investment in Legend Group. Genscript booked a US$320.4 million share of Legend’s loss and a non-cash impairment of US$398.1 million on that investment, reversing the one-off unrealised gain recorded in the prior period and highlighting the earnings volatility tied to its cell therapy exposure, though management stressed no material impact on liquidity.

The most recent analyst rating on (HK:1548) stock is a Sell with a HK$13.00 price target. To see the full list of analyst forecasts on Genscript Biotech stock, see the HK:1548 Stock Forecast page.

More about Genscript Biotech

Genscript Biotech Corporation is a biotechnology company listed in Hong Kong that provides life-science research and biopharmaceutical services. The group’s operations span biologics discovery, development, and related technology platforms, with revenue derived from licenses and a range of biotech service offerings to global customers.

YTD Price Performance: -10.71%

Average Trading Volume: 8,496,016

Technical Sentiment Signal: Sell

Current Market Cap: HK$24.12B

For a thorough assessment of 1548 stock, go to TipRanks’ Stock Analysis page.